natgillin/translations-raw huggingface dataset:
Signs and symptoms included visual disturbance, headache, seizures and altered mental status, with or without associated hypertension.
Znaki in simptomi vključujejo motnje vida, glavobol, epileptične napade in spremenjeni mentalni status s pridruženo hipertenzijo ali brez nje.
Do not drive or use any tools or machines if you experience side effects, such as dizziness, tiredness, sleepiness or blurred vision.
Vpliv na sposobnost upravljanja vozil in strojev Ne vozite ali uporabljajte katerega koli orodja ali stroja, če imate neželene učinke, kot so omotica, utrujenost, zaspanost ali zamegljen vid.
In addition, single dose administration of 0.5 mg digoxin had no apparent effect on thalidomide pharmacokinetics.
Tudi uporaba enega 0,5-mg odmerka digoksina ni imela nobenega vidnega učinka na farmakokinetiko talidomida.
Thalidomide is contraindicated during pregnancy and in women of childbearing potential unless all the conditions of the Pregnancy Prevention Programme are met (see section 4.3)
Talidomid je kontraindiciran med nosečnostjo in pri ženskah v rodni dobi, razen če so izpolnjeni vsi pogoji programa za preprečevanje nosečnosti (glejte poglavje 4.3).
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benigne, maligne in neopredeljene novotvorbe (vključno s cistami in polipi)
Animal studies have shown excretion of thalidomide in breast milk.
Študije na živalih so pokazale izločanje talidomida v materino mleko.
Amenorrhea during thalidomide therapy should be assumed to result from pregnancy, until it is medically confirmed that the patient is not pregnant.
Upoštevati morate možnost, da je amenoreja med zdravljenjem s talidomidom lahko posledica nosečnosti, dokler ni medicinsko potrjeno, da bolnica ni noseča.
• You must use one effective method of contraception: o for at least 4 weeks before starting treatment o during treatment o until at least 4 weeks after stopping treatment Your doctor will tell you what method of contraception to use.
• Uporabljati morate eno zanesljivo kontracepcijsko metodo: o vsaj 4 tedne pred začetkom zdravljenja o med zdravljenjem o vsaj 4 tedne po koncu zdravljenja Vaš zdravnik vam bo povedal, katero metodo kontracepcije uporabiti.
These patients either exhibited no symptoms or exhibited symptoms of drowsiness, irritability, “sickness,” and/or headache.
Pri teh bolnikih se simptomi niso pojavili ali pa so se pojavili simptomi zaspanosti, razdražljivosti, siljenja na bruhanje in/ali glavobola.
This may be due to blood clots in the arteries leading to your lungs (called ‘pulmonary embolism'), which is a common side effect.
Vzrok so lahko krvni strdki v arterijah, ki vodijo do vaših pljuč (imenuje se „pljučna embolija“), ki je pogost neželeni učinek.
• Prior to prescribing all healthcare professionals who intend to prescribe (and in agreement with the National Competent Authority, dispense) Thalidomide Celgene are provided with an Educational Healthcare Professional's Kit containing the following: o Educational healthcare professional booklet o Educational brochures for patient o Patient cards o Summary of product characteristics, package leaflet and labelling
• Pred predpisovanjem prejmejo vsi zdravstveni delavci, ki nameravajo predpisovati (in v skladu z dogovorom s pristojnimi nacionalnimi organi izdajati) zdravilo Thalidomide Celgene, paket izobraževalnih gradiv za zdravstvene delavce, ki vsebuje naslednje: o Izobraževalna brošura za zdravstvene delavce o Izobraževalne brošure za bolnike o Kartice za bolnike o Povzetek glavnih značilnosti zdravila, navodilo za uporabo in označevanje
These complications are caused by the break-down products of dying cancer cells and may include the following: changes to blood chemistry; high potassium, phosphorus, uric acid, and low calcium consequently leading to changes in kidney function, heart beat, seizures, and sometimes death.
Te zaplete povzročajo razgradni produkti odmirajočih rakavih celic in lahko vključujejo naslednje: spremenjene rezultate krvnih preiskav; visoko raven kalija, fosforja, sečne kisline in nizko raven kalcija, kar posledično povzroči spremembe v delovanju ledvic, utripu srca, konvulzije in včasih smrt,
The effect of thalidomide on thyroid function was assessed in both rats and dogs.
Učinek talidomida na delovanje ščitnice je bil ocenjen pri podganah in pri psih.
Dispensing of thalidomide to women of childbearing potential should occur within 7 days of the prescription and following a medically supervised negative pregnancy test result.
Izdajanje talidomida ženskam v rodni dobi je dovoljeno v 7 dneh po izdaji recepta in po zdravniško nadzorovanem negativnem testu nosečnosti.
• Decreased or abnormal sensation (dysaesthesia).
• oslabljeno ali nenormalno zaznavanje (disestezija),
It is very common that thalidomide causes somnolence.
Talidomid zelo pogosto povzroči somnolenco.
Thalidomide may cause fatigue (very common), dizziness (very common), somnolence (very common) and blurred vision (common) (see section 4.8).
Talidomid lahko povzroči utrujenost (zelo pogosto), omotico (zelo pogosto), somnolenco (zelo pogosto) in zamegljen vid (pogosto) (glejte poglavje 4.8).
Some of the cases of HBV reactivation progressed to acute hepatic failure and resulted in discontinuation of thalidomide.
Nekateri primeri reaktivacije HBV so napredovali v akutno odpoved jeter in imeli za posledico ukinitev talidomida.
The adverse reaction profile reported in patients > 75 years of age treated with thalidomide 100 mg once daily was similar to the adverse reaction profile observed in patients ≤ 75 years of age treated with thalidomide 200 mg once daily (see Table 3).
Profil neželenih učinkov, o katerih so poročali pri bolnikih, starih > 75 let, zdravljenih s talidomidom 100 mg enkrat na dan, je bil podoben profilu neželenih učinkov, ugotovljenemu pri bolnikih, starih ≤ 75 let, zdravljenih s talidomidom v odmerku 200 mg enkrat na dan (glejte preglednico 3).
Your doctor will tell you how to take Thalidomide Celgene and for how long you will need to take it (see section 2, “What you need to know before you take Thalidomide Celgene”).
Zdravnik vam bo povedal, kako vzeti zdravilo Thalidomide Celgene in koliko časa ga je treba jemati (glejte poglavje 2 „Kaj morate vedeti, preden boste vzeli zdravilo Thalidomide Celgene“).
Prior to approval by the National Competent Authority and launch of the medicinal product, the MAH should ensure that the educational materials are provided to and reviewed by the national patients' organisations or if such an organisation does not exist or can not be involved, by a relevant patients group.
Imetnik dovoljenja za promet z zdravilom mora pred odobritvijo s strani pristojnega nacionalnega organa in prihodom zdravila na trg zagotoviti, da se izobraževalno gradivo predložinacionalnim organizacijam za bolnike, da jih pregledajo, oziroma če te ne obstajajo ali če ne morejo sodelovati, zadevnim skupinam bolnikov.
Patients should be instructed not to drive cars, use machines or perform hazardous tasks while being treated with thalidomide if they feel tired, dizzy, sleepy or have blurred vison.
Bolnike je treba poučiti, da v času zdravljena s talidomidom ne smejo voziti avtomobilov, upravljati strojev ali izvajati nevarnih nalog, če so utrujeni, omotični, zaspani ali imajo zamegljen vid.
Thalidomide does not interact with hormonal contraceptives.
Med talidomidom in hormonskimi kontraceptivi ni medsebojnega delovanja.
Patients should be evaluated for signs and symptoms of underlying cardiopulmonary disease prior to initiating and during thalidomide therapy.
Bolnike je treba oceniti glede znakov in simptomov obstoječe kardiopulmonalne bolezni pred uvedbo zdravljenja s talidomidom in med njim.
• Allergic reactions such as a localised or generalised pruritic rash and angioedema (types of allergic reaction that may be manifested as hives, rashes, swelling of eyes, mouth or face, difficulty of breathing, or itching).
• alergijske reakcije kot je lokalizirani ali generalizirani pruritični izpuščaj in angioedem (vrsta alergijske reakcije, ki se lahko kaže v obliki koprivnice, izpuščajev, oteklosti oči, ust ali obraza, težav z dihanjem ali srbenja),
MP (n=193)
n (% bolnikov) MP (n=193)
A medically supervised pregnancy test should be repeated every 4 weeks, including 4 weeks after the end of treatment, except in the case of confirmed tubal sterilisation.
Test nosečnosti pod zdravniškim nadzorom je treba ponoviti vsake 4 tedne, vključno s 4 tedni po koncu zdravljenja, razen v primeru potrjene sterilizacije jajcevodov.
There is a linear relationship between body weight and estimated thalidomide clearance; in multiple myeloma patients with body weight from 47-133 kg, thalidomide clearance ranged from approximately 6-12 L/h, representing an increase in thalidomide clearance of 0.621 L/h per 10 kg body weight increase.
Med telesno maso in ocenjenim očistkom talidomida je linearno razmerje; pri bolnikih z diseminiranim plazmocitomom s telesno maso med 47 in 133 kg je bil razpon očistka talidomida med približno 6-12 l/h, kar predstavlja povečanje očistka talidomida za 0,621 l/h na 10 kg telesne mase.
• Inflammation of the cells lining your stomach wall.
• vnetje celic v steni želodca,
• A slow heart rate, heart failure.
• počasen srčni utrip, popuščanje srca,
Due to thalidomide's potential to induce bradycardia, caution should be exercised with medicinal products having the same pharmacodynamic effect such as active substances known to induce torsade de pointes, beta blockers or anticholinesterase agents.
Zaradi potenciala talidomida, da povzroči bradikardijo, je potrebna previdnost pri zdravilih, ki imajo isti farmakodinamični učinek, kot na primer zdravilne učinkovine, za katere je znano, da inducirajo torsade de pointes, zaviralci beta ali zdravila proti holinesterazi.
If you forget to take Thalidomide Celgene at your regular time and
Če ste pozabili vzeti zdravilo Thalidomide Celgene Če ste pozabili vzeti odmerek zdravila Thalidomide Celgene ob običajnem času in
• All treatment initiation forms and/or equivalent tool should contain the following elements: o Teratogenicity warning o Patients receive appropriate counselling prior to treatment initiation o Date of counselling o Affirmation of patient understanding regarding the risk of thalidomide and the PPP measures o Patient details, signature and date o Prescriber name, signature and date o Aim of this document i.e. as stated in the PPP: “The aim of the treatment initiation form is to protect patients and any possible foetuses by ensuring that patients are fully informed of and understand the risk of teratogenicity and other adverse reactions associated with the use of thalidomide.
• Vsi obrazci za začetek zdravljenja in/ali ustrezno orodje morajo vsebovati naslednje elemente: o opozorilo o teratogenosti o da so bolniki pred začetkom zdravljenja deležni ustreznega svetovanja o datum svetovanja o potrdilo o bolnikovem razumevanju v zvezi s tveganjem talidomida in ukrepi PPN o podatke bolnika, podpis in datum o ime zdravnika, ki je zdravilo predpisal, podpis in datum o namen dokumenta, tj. kot je zabeleženo v PPN: „Cilj obrazca za začetek zdravljenja je zaščititi bolnike in morebitne plode tako, da se zagotovi popolna obveščenost in razumevanje bolnikov glede tveganja teratogenosti in drugih neželenih učinkov, povezanih z uporabo talidomida.
• you have high blood pressure in the arteries of the lungs (see also section 4 “Possible side effects”).
• imate zvišan krvni tlak v pljučnih arterijah (glejte tudi poglavje 4 „Možni neželeni učinki“);
If Stevens-Johnson syndrome, TEN or DRESS is suspected, use of thalidomide should not be resumed (see section 4.2 and 4.4).
Ob sumu na Stevens-Johnsonov sindrom, TEN ali DRESS se zdravljenje s talidomidom ne sme nadaljevati (glejte poglavji 4.2 in 4.4).
• Increase in blood pressure within blood vessels that supply the lungs which can lead to shortness of breath, tiredness, dizziness, pain in the chest, a faster heartbeat, or swelling in the legs or ankles (pulmonary hypertension).
• zvišanje krvnega tlaka v krvnih žilah, ki preskrbujejo pljuča, kar lahko povzroči kratko sapo, utrujenost, omotico, bolečine v prsih, pospešen srčni utrip ali otekanje nog ali gležnjev (pljučna hipertenzija);
Consider reducing dose if symptoms worsen.
Premislite o zmanjšanju odmerka, če se simptomi poslabšajo, vendar pa ni nujno, da se bodo simptomi po zmanjšanju odmerka izboljšali.
If not established on effective contraception, the patient must be referred preferably to an appropriately trained healthcare professional for contraceptive advice in order that contraception can be initiated.
Če bolnica ne uporablja zanesljive kontracepcije, jo je treba napotiti k ustrezno usposobljenemu zdravniku na posvet glede kontracepcije, da jo lahko prične uporabljati.
A cumulative search of DRESS cases with thalidomide from spontaneous sources and clinical trials retrieved 8 cases among which 4 cases were assessed as probable or possible drug reaction with eosinophilia and systemic symptoms (DRESS) as per Regiscar criteria.
Pri kumulativnem iskanju primerov DRESS pri uporabi talidomida iz spontanih virov in kliničnih preskušanj so našli 8 primerov, od katerih so 4 primere ocenili kot verjetno ali možno reakcijo na zdravilo z eozinofilijo in sistemskimi simptomi (DRESS) po merilih Regiscar.
Venous and arterial thromboembolic events
Venski in arterijski trombembolični dogodki
If you are not sure, talk to your doctor or pharmacist before taking Thalidomide Celgene.
Če ste negotovi, se posvetujte z zdravnikom ali farmacevtom, preden vzamete zdravilo Thalidomide Celgene.
Some of the cases of herpes zoster reactivation resulted in disseminated herpes zoster, requiring a temporary hold of the treatment with thalidomide and adequate antiviral treatment.
Nekateri primeri reaktivacije herpesa zostra so napredovali v diseminirani herpes zoster, zaradi katerega je bilo treba začasno prekiniti zdravljenje s talidomidom in uvesti ustrezno protivirusno zdravljenje.
Thalidomide is a powerful human teratogen, inducing a high frequency (about 30 %) of severe and live-threatening birth defects such as: ectromelia (amelia, phocomelia, hemimelia) of the upper and/or lower extremities, microtia with abnormality of the external acoustic meatus (blind or absent), middle and internal ear lesions (less frequent), ocular lesions (anophthalmia, microphthalmia), congenital heart disease, renal abnormalities.
Talidomid je močan humani teratogen, ki inducira visoko pogostnost (okrog 30 %) resnih in smrtno nevarnih prirojenih okvar, kot so: ektromelija (amelija, fokomelija, hemimelija) zgornjih in/ali spodnjih okončin, mikrotija z okvarami zunanjega slušnega kanala (slep ali manjkajoč), lezije srednjega in notranjega ušesa (manj pogosto), lezije oči (anoftalmija, mikroftalmija), prirojena srčna bolezen, okvare ledvic.
Hepatic disorders, mainly abnormal liver test results, were reported.
Poročali so o boleznih jeter, v glavnem o nenormalnih rezultatih jetrnih testov.
Medically supervised pregnancy tests with a minimum sensitivity of 25 mIU/ml must be performed for women of childbearing potential as outlined below.
Pri ženskah v rodni dobi je treba izvesti test nosečnosti pod zdravniškim nadzorom z minimalno občutljivostjo 25 m i.e./ml, kot je opisano spodaj.
Acute myeloid leukaemia*
pogosti akutna mieloična levkemija*,^
The initial dose of melphalan is reduced for elderly > 75 years of age considering baseline bone marrow reserve and renal function.
Začetni odmerek melfalana je treba pri bolnikih, starejših od > 75 let, zmanjšati, pri čemer upoštevamo izhodiščno rezervo kostnega mozga in funkcijo ledvic.
If you are not sure if any of the above apply to you, talk to your doctor before taking Thalidomide Celgene.
Če ste negotovi, ali se kar koli od zgoraj naštetega nanaša na vas, se posvetujte z zdravnikom, preden vzamete zdravilo Thalidomide Celgene.
• Do not break, open or chew the capsules.
• Kapsul ne zdrobite, odprite ali žvečite.
If you do become pregnant during the treatment with thalidomide, you must stop the treatment and inform your doctor immediately.
Če v času zdravljenja s talidomidom zanosite, morate zdravljenje takoj ustaviti in o tem obvestiti zdravnika.
Non-enzymatic hydrolysis of thalidomide, being the primary clearance mechanism, suggests that the potential for drug-drug interactions with thalidomide is low.
Neencimska hidroliza talidomida, ki je primarni mehanizem izločanja, kaže, da je možnost interakcij med zdravili majhna.
Medicinal products known to cause peripheral neuropathy Medicinal products known to be associated with peripheral neuropathy (e.g. vincristine and bortezomib) should be used with caution in patients receiving thalidomide.
Zdravila, za katera je znano, da povzročajo periferno nevropatijo (npr. vinkristin, bortezomib), morajo bolniki, ki prejemajo talidomid, jemati s previdnostjo.
Cases of viral reactivation have been reported in patients receiving thalidomide, including serious cases of herpes zoster or hepatitis B virus (HBV) reactivation.
Pri bolnikih, ki so prejemali talidomid, so poročali o primerih reaktivacije virusov, vključno z resnimi primeri reaktivacije virusa herpes zoster ali virusa hepatitisa B (HBV - hepatitis B virus).
A study in rabbits demonstrated no effect on fertility indices in males or females although testicular degeneration was observed in males.
Študije na kuncih niso pokazale nobenega učinka na kazalce plodnosti samcev ali samic kljub testikularni degeneraciji, opaženi pri samcih.
The melphalan recommended starting dose is 0.1 to 0.2 mg/kg daily according to bone marrow reserve along with a further 50 % dose reduction for moderate (creatinine clearance: ≥ 30 but < 50 mL/minute) or severe (CrCl: < 30 mL/minute) renal insufficiency.
Priporočeni začetni odmerek melfalana je 0,1 do 0,2 mg/kg na dan glede na rezervo kostnega mozga, odmerek se zmanjša še za nadaljnjih 50 % pri zmerni (očistek kreatinina: ≥ 30, vendar < 50 ml/minuto) ali hudi (CrCl: < 30 ml/minuto) insuficienci ledvic.
• you have kidney or liver problems (see also section 4 “Possible side effects”).
• imate težave z ledvicami ali jetri (glejte tudi poglavje 4 „Možni neželeni učinki“).
In addition to thalidomide, hydrolytic products N-(o-carboxybenzoyl) glutarimide and phthaloyl isoglutamine formed via non-enzymatic processes are also present in plasma and in majority in urine.
Poleg talidomida sta v plazmi in v večji meri v urinu prisotna hidrolitična produkta N-(o-karboksibenzoil) glutarimid in ftaloil izoglutamin, ki nastaneta z neencimskimi procesi.
The prescriber must ensure that:
Zdravnik, ki predpiše zdravilo, mora zagotoviti naslednje:
• Patient cards and/or equivalent tools: o verification that appropriate counselling has taken place o documentation of childbearing potential status o check box (or similar) which physician ticks to confirm that patient is using effective contraception (if woman of childbearing potential) o verification of initial negative pregnancy test prior to start of treatment (if woman of childbearing potential) o pregnancy test dates and results
• Kartice za bolnike in/ali ustrezno orodje: o potrdilo o ustreznem svetovanju o dokumentacijo o statusu plodnosti o kontrolno okence (ali podobno) kjer zdravnik potrdi, da bolnik uporablja zanesljivo kontracepcijo (za ženske v rodni dobi) o potrdilo o začetnem negativnem testu nosečnosti pred začetkom zdravljenja (za ženske v rodni dobi) o datume testov nosečnosti in izide
for 4 days had no effect on the international normalized ratio (INR) in healthy volunteers.
Večkratni odmerki po 200 mg talidomida, enkrat na dan 4 dni, niso imeli učinka na internacionalno normalizirano razmerje (INR - international normalized ratio) pri zdravih prostovoljcih.
o The capsule shell contains gelatin and titanium dioxide (E171).
o Ovojnica kapsule vsebuje želatino in titanov dioksid (E171).
Results from IFM 99-06, a Phase 3, randomised, open label, parallel group, multicentre study have demonstrated a survival advantage when thalidomide is used in combination with melphalan and prednisone for 12 cycles of 6 weeks in the treatment of newly diagnosed multiple myeloma patients.
Rezultati randomizirane, odprte, multicentrične študije IFM 99-06 III. faze s paralelnimi skupinami so pokazali prednost preživetja pri uporabi talidomida v kombinaciji z melfalanom in prednizonom 12 ciklov po 6 tednov pri zdravljenju bolnikov z novo diagnosticiranim diseminiranim plazmocitomom.
The reported events occurred in young (premenopausal) women (median age 36 years) receiving thalidomide for non-multiple myeloma indications, had an onset within 6 months of initiating treatment and reversed upon discontinuation of thalidomide.
Dogodke, o katerih so poročali, so zabeležili pri mladih (predmenopavznih) ženskah (mediana starost 36 let), ki so se zdravile s talidomidom zaradi indikacij, ki niso bile diseminirani plazmocitom, z začetkom v 6 mesecih od uvedbe zdravljenja, izzveneli pa so po ukinitvi talidomida.
Thalidomide interruption or discontinuation should be considered for Grade 2-3 skin rash.
O prekinitvi ali ukinitvi talidomida je treba razmisliti pri izpuščaju 2.-3. stopnje.
• All educational brochures for patients should contain the following information o That thalidomide is teratogenic o That thalidomide may cause ischaemic heart disease, (including myocardial infarction) o Description of the patient card and its use in the individual Member State o Guidance on handling Thalidomide Celgene for patients, caregivers and family members o National or other applicable specific arrangements for a prescription for thalidomide to be dispensed o That thalidomide must not be given to any other person o That the patient should not donate blood o That the patient should tell their doctor about any adverse events o That any unused capsules should be returned to the pharmacist at the end of the treatment
• Vse izobraževalne brošure za bolnike morajo zajemati naslednje informacije o da je talidomid teratogen o da talidomid lahko povzroči ishemično bolezen srca (vključno z miokardnim infarktom) o opis kartice za bolnika in njeno uporabo v posameznih državah članicah o smernice za ravnanje z zdravilom Thalidomide Celgene za bolnike, skrbnike in družinske člane o nacionalne ali druge ustrezne posebne dogovore glede predpisovanja in izdajanja talidomida o da se talidomida ne sme dati nikomur drugemu o da bolniki ne smejo darovati krvi o da morajo bolniki zdravnika obvestiti o vseh neželenih učinkih o da je treba ob koncu zdravljenja vse neporabljene kapsule vrniti farmacevtu
• Kidney disease (renal failure).
• bolezen ledvic (ledvična odpoved).
Table 1: Starting doses for thalidomide in combination with melphalan and prednisone Age (years)
Preglednica 1: Začetni odmerki talidomida v kombinaciji z melfalanom in prednizonom Starost (leta)
Patients should be monitored for liver function, particularly in case of pre-existing liver disorder or concomitant use of medicinal product susceptible to induce liver dysfunction (see section 4.8).
Pri bolnikih je treba spremljati delovanje jeter, posebno v primeru obstoječe bolezni jeter ali sočasnega jemanja zdravil, ki lahko povzročijo disfunkcijo jeter (glejte poglavje 4.8).
• Viral infections, including herpes zoster (also known as ‘shingles', a viral disease that causes a painful skin rash with blisters) and recurrence of hepatitis B infection (which can cause yellowing of the skin and eyes, dark brown-coloured urine, right-sided stomach pain, fever and feeling nauseous or being sick).
• virusne okužbe, vključno s herpesom zostrom (ki je znan tudi kot ‘pasovec', virusna bolezen, ki povzroča boleč kožni izpuščaj z mehurčki) in ponovitvijo okužbe z virusom hepatitisa B (ki lahko povzroči porumenelost kože in oči, temno rjavo obarvan urin, bolečino desno v trebuhu, zvišano telesno temperaturo in slabost s siljenjem na bruhanje);
Melphalan dosing: reduce by 50 % for moderate (creatinine clearance: ≥ 30 but < 50 mL/min) or severe (CrCl: < 30mL/min) renal insufficiency e
d Odmerjanje melfalana: zmanjšajte odmerek za 50 % pri zmerni (očistek kreatinina: ≥ 30, vendar < 50 ml/min) ali hudi (CrCl: < 30ml/min)